Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis.

Dermatology and therapy·2026
Same author

European Dermatologists' Perception and Awareness of Teledermatology Use: Results From an International Survey Promoted by the EADV Teledermatology Task Force.

International journal of dermatology·2026
Same author

Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study.

Journal of the American Academy of Dermatology·2026
Same author

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Dermatology and therapy·2026
Same author

Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.

Nature medicine·2025

Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K

German psoriasis registry PsoBest: objectives, methodology and baseline data.

Matthias Augustin1, Christina Spehr, Marc A Radtke

  • 1IVDP - Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|January 8, 2014
PubMed
Summary

The PsoBest registry tracks long-term psoriasis outcomes. Patients in this study had higher disease severity and more psoriatic arthritis than in a previous national study.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

6.6K

Related Experiment Videos

Last Updated: May 4, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

6.6K

Area of Science:

  • Dermatology
  • Clinical Research
  • Public Health

Background:

  • The German Psoriasis Registry (PsoBest) collects data on long-term psoriasis management.
  • It focuses on efficacy, safety, patient-reported benefits, and treatment strategies.

Purpose of the Study:

  • To establish baseline characteristics of patients initiating new systemic or biologic therapy for moderate to severe psoriasis.
  • To compare these baseline characteristics with a national health care study (PsoHealth 2007).

Main Methods:

  • PsoBest enrolled patients starting their first conventional systemic agent or biologic for moderate to severe psoriasis.
  • Data were collected via standardized physician and patient forms over a five-year observation period.
  • Baseline data from patients recruited by December 31, 2012, were analyzed.

Main Results:

  • 2,556 patients were recruited from 199 centers, with 808 receiving biologics and 1,651 conventional systemic therapy.
  • PsoBest patients exhibited higher disease severity (PASI, DLQI, EQ-5D VAS) compared to PsoHealth 2007.
  • PsoBest patients had shorter disease duration, were younger, and had higher rates of psoriatic arthritis and nail psoriasis.

Conclusions:

  • Patients enrolled in the PsoBest registry represent a population with a high disease burden.
  • This highlights the need for effective long-term management strategies for severe psoriasis.